Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of bortezomib and sorafenib
tosylate when given together with decitabine in treating patients with acute myeloid
leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine,
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving bortezomib and
sorafenib tosylate together with decitabine may work better in treating acute myeloid
leukemia.